Home/Pipeline/LUPKYNIS (voclosporin)

LUPKYNIS (voclosporin)

Lupus Nephritis

ApprovedCommercial

Key Facts

Indication

Lupus Nephritis

Phase

Approved

Status

Commercial

Company

Aurinia Pharmaceuticals

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals is a Canadian biotech company with a mission to deliver transformative therapies for autoimmune diseases. Its core achievement is the successful FDA approval and commercialization of LUPKYNIS, a first-in-class oral treatment for lupus nephritis. The company's strategy is to maximize the global potential of LUPKYNIS while leveraging its expertise to develop a pipeline of novel candidates, including a dual BAFF/APRIL inhibitor, to build a sustainable, multi-product autoimmune franchise.

View full company profile

Therapeutic Areas

Autoimmune Diseases Nephrology Rheumatology

Other Lupus Nephritis Drugs

Drug	Company	Phase	Status
hCDR1 (Edratide)	XTL Biopharmaceuticals	Phase 1/2	Active/Completed
Ramatroban (KAR101)	KARE Biosciences	Preclinical	Active
Anti-iRhom2 antibodies	SciRhom	Pre-clinical	Active
KYV-101 (mivocabtagene autoleucel)	Kyverna Therapeutics	Phase 2	Active, not recruiting
NKX019	Nkarta	Phase 1	Active
Zetomipzomib (KZR-616)	Kezar Life Sciences	Phase 2	Discontinued